Financial StabilityManagement estimates its cash holdings to sufficiently fund its operations through the first quarter of 2028, allowing for the full funding of the upcoming imdusiran Phase 2b trial.

Legal ProceedingsA positive outcome to the Markman hearing was viewed as favorable for Arbutus.

Therapeutic DevelopmentsAnalyst recommends a Buy rating, affirming confidence in the potential of imdusiran as a core component for achieving a functional cure in HBV.

Bears Say

Key RisksKey risks include failed or equivocal studies, unforeseen safety or tolerability issues, meaningful delays, and the inability to sufficiently fund operations.

Restructuring CostsArbutus anticipates a one-time restructuring charge of ~$11M-$13M in 1Q25.

Trial DiscontinuationArbutus has discontinued the planned IM-PROVE III Phase 2a trial of imdusiran plus anti-PD-L1 antibody durvalumab prior to initiation.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

1.17% Insiders

10.57% Mutual Funds

0.07% Other Institutional Investors

78.25% Public Companies and

Individual Investors

Detailed Ownership Overview >

ABUS FAQ

What was Arbutus Biopharma Corporation’s price range in the past 12 months?

Arbutus Biopharma Corporation lowest stock price was $2.71 and its highest was $4.72 in the past 12 months.

What is Arbutus Biopharma Corporation’s market cap?

Arbutus Biopharma Corporation’s market cap is $599.48M.

When is Arbutus Biopharma Corporation’s upcoming earnings report date?

Arbutus Biopharma Corporation’s upcoming earnings report date is Jul 31, 2025 which is in 8 days.

How were Arbutus Biopharma Corporation’s earnings last quarter?

Arbutus Biopharma Corporation released its earnings results on May 14, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.104 by -$0.026.

Is Arbutus Biopharma Corporation overvalued?

According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arbutus Biopharma Corporation pay dividends?

Arbutus Biopharma Corporation does not currently pay dividends.

What is Arbutus Biopharma Corporation’s EPS estimate?

Arbutus Biopharma Corporation’s EPS estimate is -0.05.

How many shares outstanding does Arbutus Biopharma Corporation have?

Arbutus Biopharma Corporation has 191,527,130 shares outstanding.

What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?

Arbutus Biopharma Corporation reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.104. Following the earnings report the stock price went down -0.94%.

Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?

Currently, no hedge funds are holding shares in ABUS

Arbutus Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-79.02%

Trailing 12-Months

Asset Growth

-22.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS) is a biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for chronic hepatitis B virus (HBV) infection. Operating in the biotechnology sector, Arbutus focuses on leveraging its proprietary lipid nanoparticle (LNP) technology and RNA interference (RNAi) therapeutic approaches to develop innovative treatments aimed at addressing unmet medical needs in viral diseases.